Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRADA study of once-daily raltegravir and atazanavir in suppressed HIV-1 infection
NL-OMON33412Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltegravir, atazanavir, lamivudine and emtricitabine in Human immunodeficiency virus infection type 1, sponsored by Radboud University Medical Center. Primary endpoint: Raltegravir pharmacokinetics. Started Sep 2009; status: active, not recruiting.
02
Drugs
raltegraviratazanavirlamivudineemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON33412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33412.